Meridian Bioscience (VIVO) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. AMD

Go back to Meridian Bioscience (VIVO) Reports In-Line Q2 EPS

Meridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance

April 28, 2016 7:45 AM EDT

GENERAL HIGHLIGHTS

CINCINNATI, April 28, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., (NASDAQ: VIVO) today:

reported fiscal 2016 second quarter and first six months net revenues of $51.3 million and $98.4 million, respectively, decreases of 1% from the same periods of the prior fiscal year; reported second quarter operating income of $15.2 million (including $1.2 million of costs associated with acquisition activity), a decrease of 4% from the same period of the prior fiscal year;... More

Meridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae

April 27, 2016 7:00 AM EDT

CINCINNATI, April 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received the CE Mark for a new molecular diagnostic test for Mycoplasma pneumonia (M. pneumoniae). The new and improved illumigene Mycoplasma Direct assay features a simplified procedure compared to the existing illumigene Mycoplasma product. The new procedure will significantly expand Meridians customer base by eliminating the need for specialized techniques and training, as well as providing definitive results in less... More